Page last updated: 2024-11-07

2,3-bis(3'-hydroxybenzyl)butane-1,4-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-bis(3'-hydroxybenzyl)butane-1,4-diol: lignan isolated from urine of humans & other mammals [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123725
CHEBI ID182489
SCHEMBL ID2641390
MeSH IDM0094087

Synonyms (19)

Synonym
2,3-bis[(3-hydroxyphenyl)methyl]butane-1,4-diol
CHEBI:182489
2,3-bhbbd
1,4-butanediol, 2,3-bis((3-hydroxyphenyl)methyl)-
2,3-bis((3-hydroxyphenyl)methyl)-1,4-butanediol
2,3-bis(3-hydroxybenzyl)butane-1,4-diol
2,3-bis(3'-hydroxybenzyl)butane-1,4-diol
compound 180/410
76543-16-3
enterodiol, >=95.0% (hplc)
FT-0667867
918502-74-6
SCHEMBL2641390
3,3'-[2,3-bis(hydroxymethyl)butane-1,4-diyl]diphenol
DWONJCNDULPHLV-UHFFFAOYSA-N
(+/-)-enterodiol
(+/-)-enterodiol-13c3
FT-0667868
DTXSID10861023

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters and urinary excretion of enterodiol and enterolactone were evaluated after consumption of their purified plant precursor, secoisolariciresinol diglucoside (SDG)."( Pharmacokinetics of enterolignans in healthy men and women consuming a single dose of secoisolariciresinol diglucoside.
Arts, IC; Hollman, PC; Kuijsten, A; Vree, TB, 2005
)
0.33
" These data suggest a similar pharmacokinetic profile between the enriched and polymer form of SDG, providing support for the use of SDG polymer as a more economical precursor for SECO, ED, and EL in applications of chronic disease management."( Oral Pharmacokinetics of Enriched Secoisolariciresinol Diglucoside and Its Polymer in Rats.
Alcorn, J; Guo, Y; Mustafa, R; Purdy, SK; Reaney, MJT; Shen, J; Tse, TJ; Yang, X, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study determined the effect of the mammalian lignans enterolactone (ENL) and enterodiol (END) alone and in combination with the isoflavone genistein (GEN) on the growth of MCF-7 tumors in ovariectomized nude mice."( Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice.
Chen, JM; Power, KA; Saarinen, NM; Thompson, LU, 2006
)
0.33

Bioavailability

ExcerptReferenceRelevance
" More research is warranted to determine the bioavailability of lignins in the human diet."( Dietary lignins are precursors of mammalian lignans in rats.
Adlercreutz, H; Begum, AN; Fukushima, K; Heinonen, SM; Lapierre, C; Mila, I; Nagano, K; Nicolle, C; Rémésy, C; Scalbert, A, 2004
)
0.32
" For a proper evaluation of potential health effects of enterolignans, information on their bioavailability is essential."( The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed.
Arts, IC; Hollman, PC; Kuijsten, A; van't Veer, P, 2005
)
0.33
" In conclusion, the bioavailability of phytoestrogens, especially when given in mixtures, is subject to high interindividual variation."( Cosupplementation of isoflavones, prenylflavonoids, and lignans alters human exposure to phytoestrogen-derived 17beta-estradiol equivalents.
Bolca, S; Bracke, M; De Keukeleire, D; Depypere, H; Heyerick, A; Possemiers, S; Verstraete, W; Wyns, C, 2009
)
0.35
" These results indicate that SDG hydrolysis is not a common feature in Bifidobacterium genus, but selected probiotic strains can be combined to β-glucoside-based prebiotics to enhance the release of SECO, thus improving its bioavailability for absorption by colonic mucosa and/or the biotransformation to ED and EL by other intestinal microorganisms."( Role of bifidobacteria in the activation of the lignan secoisolariciresinol diglucoside.
Amaretti, A; Leonardi, A; Raimondi, S; Roncaglia, L; Rossi, M, 2011
)
0.37
"Consumption of flaxseed lignans is associated with various health benefits; however, little is known about the bioavailability of purified lignans in flaxseed."( Comparative pharmacokinetics of purified flaxseed and associated mammalian lignans in male Wistar rats.
Alcorn, J; Krol, ES; Muir, AD; Mukker, JK; Singh, RS, 2015
)
0.42
" The extent of SDG release from the polymer and subsequent bioavailability of SDG metabolites are unknown."( Oral Pharmacokinetics of Enriched Secoisolariciresinol Diglucoside and Its Polymer in Rats.
Alcorn, J; Guo, Y; Mustafa, R; Purdy, SK; Reaney, MJT; Shen, J; Tse, TJ; Yang, X, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (126)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (8.73)18.7374
1990's20 (15.87)18.2507
2000's44 (34.92)29.6817
2010's43 (34.13)24.3611
2020's8 (6.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.86 (24.57)
Research Supply Index4.97 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (9.16%)5.53%
Reviews5 (3.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.76%)0.25%
Other113 (86.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]